Non-invasive tests for clinically significant portal hypertension after HCV cure

Semmler, Georg; Lens, Sabela; Meyer, Elias Laurin; Baiges, Anna; Alvarado‐Tapias, Edilmar; Llop, Elba; Téllez, Luís; Mauro, Ezequiel; Escudé, Laia; Díez, Cristina; Ibáñez‐Samaniego, Luis; Puente, Ángela; Fortea, José Ignacio; Abadía, Marta; Zanetto, Alberto; Conthe, Andrés; Hernández-Évole, Helena; Scheid, Irina Sofia Luzko; Jia, Jidong; Yoshiji, Hitoshi; Francque, Sven; Tsochatzis, Emmanuel; Russo, Francesco Paolo; Crespo, Gonzalo; Forns, Xavier; Villanueva, Càndid; Hernández‐Gea, Virginia; Reiberger, Thomas; Bosch, Jaume; García‐Pagán, Juan Carlos; Mandorfer, Mattias

doi:10.1016/j.jhep.2022.08.025

Cited by 50 publications

(24 citation statements)

References 42 publications

(57 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…There were a significant proportion of patients falling within the grey zone, which was also demonstrated in a recent study by the author [9]. One should not be surprise because this is consistent with the performance of transient elastography to exclude or include patients with advanced fibrosis.…”

Section: Correspondencesupporting

confidence: 83%

Correspondence on Editorial regarding “Baveno-VII criteria to predict decompensation and initiate non-selective beta-blocker in compensated advanced chronic liver disease patients”

et al. 2023

View full text Add to dashboard Cite

Section: Correspondencesupporting

confidence: 83%

Correspondence on Editorial regarding “Baveno-VII criteria to predict decompensation and initiate non-selective beta-blocker in compensated advanced chronic liver disease patients”

et al. 2023

View full text Add to dashboard Cite

“…However, these promising observations remain to be confirmed in larger network studies. Of note, non-invasive tests for the assessment of portal pressure following etiological therapy have only been validated for HCV [ 33 ] and lack validation in HBV and HDV. Therefore, we argue that based on the association of virologic and HVPG response, the efficacy of therapies targeting HDV in patients with portal hypertension should be measured by their impact on invasively measured portal pressure.…”

Section: Blv In Patients With Advanced Chronic Liver Disease (Cirrhosis)mentioning

confidence: 99%

Treatment of Chronic Hepatitis D with Bulevirtide—A Fight against Two Foes—An Update

Ferenci

Reiberger²,

Jachs³

2022

Cells

Self Cite

View full text Add to dashboard Cite

HDV infection frequently causes progression to cirrhosis and hepatocellular carcinoma (HCC). In summer 2020, the first potentially effective drug Bulevirtide (BLV) has been approved for the treatment of HDV by the EMA. BLV is a synthetic N-acylated pre-S1 lipopeptide that blocks the binding of HBsAg-enveloped particles to the sodium taurocholate co-transporting polypeptide (NTCP), which is the cell entry receptor for both HBV and HDV. In this review, we discuss the available data from the ongoing clinical trials and from “real world series”. Clinical trials and real-world experiences demonstrated that BLV 2 mg administered for 24 or 48 weeks as monotherapy or combined with pegIFNα reduces HDV viremia and normalizes ALT levels in a large proportion of patients. The combination of BLV and pegIFNα shows a synergistic on-treatment effect compared with either one of the monotherapies.

show abstract

“…In 2022, Semmler et al studied the diagnostic efficiency of LSM/platelet count (PLT) in clinically significant portal hypertension in patients who have received successful antiviral therapy after HCV infection. Their study found the condition that LSM < 12 kPa and PLT > 150 g/L after HCV treatment could rule out the possibility of clinically significant portal hypertension with a sensitivity of 99.2% [ 21 ]. A multicenter study in Switzerland, France, and Spain, which included 155 patients with porto-sinusoidal vascular liver disease (PSVD) and 273 patients with liver cirrhosis, pointed out that LSM-using transient elastography (TE-LSM) could help to judge the presence of portal hypertension.…”

Section: Diagnosis Of Portal Hypertension Via Liver Stiffness Measure...mentioning

confidence: 99%

Application of Ultrasound Elastography in Assessing Portal Hypertension

et al. 2022

View full text Add to dashboard Cite

Portal hypertension is a common manifestation in late-to-end-stage liver diseases and can cause severe complications such as ascites, hepatic encephalopathy, etc. However, an early diagnosis of portal hypertension is often difficult as it can be asymptomatic. Though the gold standard to diagnose portal hypertension is hepatic vein catheterization, ultrasound elastography is regarded as a noninvasive alternative that can be used to accurately predict portal hypertension and a few further complications such as gastro-esophageal varices. Since ultrasound elastography is available in most medical centers, and is cheaper and noninvasive, studying its function in predicting portal hypertension is of paramount importance. Therefore, this review generalized the results of recently published articles in order to establish the indicators that were related to diagnostic and prediction efficiency. Our study found that various technologies of ultrasound elastography could be used to predict portal hypertension with satisfactory diagnostic sensitivity, specificity, accuracy, and AUC. Meanwhile, we also recognized similar diagnostic efficiency of ultrasound elastography in gastro-esophageal varices.

show abstract

Non-invasive tests for clinically significant portal hypertension after HCV cure

Cited by 50 publications

References 42 publications

Correspondence on Editorial regarding “Baveno-VII criteria to predict decompensation and initiate non-selective beta-blocker in compensated advanced chronic liver disease patients”

Correspondence on Editorial regarding “Baveno-VII criteria to predict decompensation and initiate non-selective beta-blocker in compensated advanced chronic liver disease patients”

Treatment of Chronic Hepatitis D with Bulevirtide—A Fight against Two Foes—An Update

Application of Ultrasound Elastography in Assessing Portal Hypertension

Contact Info

Product

Resources

About